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redischarge B-Type Natriuretic Peptide
ssay for Identifying Patients at High Risk of
e-Admission After Decompensated Heart Failure
amien Logeart, MD,* Gabriel Thabut, MD,† Patrick Jourdain, MD,§ Christophe Chavelas, MD,*
ascale Beyne, PHD,‡ Florence Beauvais, MD,* Erik Bouvier, MD,* Alain Cohen Solal, MD, PHD*
lichy and Pontoise, France
OBJECTIVES The aim of this study was to determine the value of serial B-type natriuretic peptide (BNP)
assay for predicting post-discharge outcome of patients admitted for decompensated
congestive heart failure (CHF).
BACKGROUND Patients hospitalized for decompensated CHF are frequently re-admitted. Thus, identifica-
tion of high-risk patients before their discharge is a major issue that remains challenging.
B-type natriuretic peptide measurement could be useful.
METHODS Serial BNP measurements were performed from admission to discharge in two samples of
consecutive patients. Survivors were monitored for six months; the main end point combined
death or first re-admission for CHF.
RESULTS Among the 105 survivors of the derivation study, all serial BNP values, percentage change in
BNP levels, and predischarge Doppler mitral pattern correlated with the outcome. In
contrast, clinical variables and left ventricular ejection fraction were poorly predictive. The
predischarge BNP assay had the best discriminative power (area under the receiver operating
characteristic [ROC] curve  0.80) and remained the lone significant variable in multivariate
analysis (hazard ratio [HR]  1.14 [95% confidence interval {CI}, 1.02 to 1.28], p  0.027).
Among the 97 survivors of the validation study, the predischarge BNP assay was also the most
predictive parameter (area under the ROC curve  0.83). The risk of death or re-admission
increased in stepwise fashion across increasing predischarge BNP ranges (p  0.0001). After
adjustment for baseline covariables, the HRs were 5.1 [95% CI 2.8 to 9.1] for BNP levels
between 350 and 700 ng/l and 15.2 [95% CI 8.5 to 27] for BNP levels 700 ng/l, compared
with BNP 350 ng/l.
CONCLUSIONS High predischarge BNP assay is a strong, independent marker of death or re-admission after
decompensated CHF, more relevant than common clinical or echocardiographic parameters
and more relevant than changes in BNP levels during acute cares. (J Am Coll Cardiol 2004;
43:635–41) © 2004 by the American College of Cardiology Foundationp
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Seart failure (HF) is a major reason for hospitalization and
epresents a huge cost for national health care budgets. Hos-
italization for decompensated congestive heart failure (CHF)
arries a poor vital prognosis, with frequent subsequent re-
dmissions (1–5). It has recently been shown that outcome can
e improved in high-risk patients by treatment intensification
nd home-based interventions (6,7). However, there is cur-
ently no simple clinical criterion or score for predicting early
utcome after discharge (8) and, thus, for identifying patients
ho require such caution. Doppler echocardiography is largely
sed in hospitalized patients and can help to stratify patients.
ndeed, Doppler analysis of left ventricular (LV) filling param-
ters has been linked to outcome after myocardial infarction
nd in dilated cardiomyopathy (9,10), including in the setting
f hospitalization (11).
From *Service de Cardiologie, †Service de Pneumologie, ‡Laboratoire de Bio-
himie, Hoˆpital Beaujon, Clichy, France; and §Service de Cardiologie, Hoˆpital Rene´
ubos, Pontoise, France. Supported, in part, by a grant from the French Federation
f Cardiology, Paris, France. Drs. Logeart and Thabut contributed equally to this
ork. Marc A. Silver, MD, acted as guest editor for this paper.
Manuscript received March 9, 2003; revised manuscript received September 10,c003, accepted September 17, 2003.The B-type natriuretic peptide (BNP) serum level is a
romising cardiac marker in various HF settings, especially
ecause of the advent of rapid assays. Indeed, BNP is secreted
y overloaded LV, and its blood level is related to severity of
V dysfunction and CHF. B-type natriuretic peptide has
iagnostic value in acute dyspnea (12–14); BNP also has
rognostic value after myocardial infarction (15,16), as well as
n outpatients with chronic CHF and systolic dysfunction
17–19). Despite potential interest, the prognostic relevance of
NP assay has been poorly investigated in the setting of
atients admitted for decompensated CHF.
The aims of this study were to determine the prognostic
alue of serial BNP assay in consecutive patients hospi-
alized for severely decompensated CHF for the predic-
ion of early death or re-admission for CHF, and to
ompare it to common clinical and echocardiographic
haracteristics.
ETHODS
tudy design. The study was approved by local ethics
ommittees. Consecutive patients admitted to the cardiol-
o
e
i
a
C
g
i
f
c
p
a
s
d
u
p
s
d
w
n
s
e
e
d
p
a
c
s
t
m
a
h
P
r
s
t
p
d
t
w
B
p
a
(
a
s
p
T
v
p
D
e
(
w
v
a
m
fi
t
“
t
2

“
w
m
b
i
s
t
m
S
b
L
y
B
w
m
p
m
l
p
r
m
w
i
v
B
u
o
f
a
d
o
(
v
A
636 Logeart et al. JACC Vol. 43, No. 4, 2004
BNP Assay and Heart Failure Outcome February 18, 2004:635–41gy department for decompensated CHF were enrolled,
xcept in the following circumstances: acute myocardial
nfarction, severe valve disease, surgical patients, or poor
dherence to therapy. The diagnosis of decompensated
HF was confirmed by two senior cardiologists using the
enerally accepted Framingham criteria and corroborative
nformation including the hospital course and results of
urther cardiac tests. On admission, a blood sample was
ollected for BNP measurement. Standard treatment was
rescribed daily by senior cardiologists. Blood samples were
lso collected every day for serial BNP assay. A final blood
ample was collected either on the day of discharge or on the
ay before discharge (predischarge values). B-type natri-
retic peptide assays were performed after discharge of
atient, and results were kept blinded until the end of the
tudy. Doppler echocardiograms were performed before
ischarge, in order to assess LV ejection fraction (LVEF) as
ell as Doppler mitral inflow pattern and systolic pulmo-
ary artery pressure. The discharge was decided by two
enior cardiologists in charge of the HF unit, using clinical
xamination, biological tests (except BNP measurements),
lectrocardiogram, and chest radiograms. Patients were
ischarged when they presented no more sign of decom-
ensation, stable blood pressure as well as renal function,
nd optimal achievement of diuretics and angiotensin-
onverting enzyme inhibitor dosages. Outcome during the
ix months after discharge was determined in every case, by
elephoning the patient or the general practitioner. The
ain end point combined death or first unscheduled re-
dmission for CHF. Re-admission for CHF was defined by
ospitalization for decompensated CHF.
atients. In the derivation study, 127 patients were en-
olled in a single center (Beaujon Hospital); 13 were
ubsequently excluded because of requirement for emergent
ransplantation, transfer to another hospital, absence of
redischarge BNP measurement, or rectified non-CHF
iagnosis, and, thus, 114 patients were finally included in
he derivation study. In the validation study, 109 patients
ere included in another center (Pontoise Hospital).
NP assay. Blood was collected into tubes containing
otassium EDTA (1 mg/ml blood), and plasma was stored
t 80°C for blinded BNP assay with the Triage BNP test
Biosite Diagnostics Inc., San Diego, California). Triage is
Abbreviations and Acronyms
BNP  B-type natriuretic peptide
CHF  congestive heart failure
DTE  deceleration time of E-wave
HF  heart failure
HR  hazard ratio
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
ROC  receiver operating characteristicpoint-of-care method based on fluorescence immunoas- Way, and can be used to quantify BNP in whole blood or
lasma. At time of the study, the working range of the
riage BNP assay was 5.0 to 1,300 ng/l, and samples with
alues exceeding 1,300 ng/l were, thus, diluted with normal
lasma and retested.
oppler echocardiography. Doppler echocardiographic
xaminations were performed with a Hewlett Packard
Andover, Massachusetts) Sonos 5500 machine equipped
ith a 2.5-MHz probe. Each examination was recorded on
ideotape for subsequent blind analysis. Pulsed Doppler
nalysis of mitral inflow included measurements of the
itral valve early peak filling velocity (E), the late peak
lling velocity (A), the E to A ratio, and the deceleration
ime of E-wave (DTE), and yielded three patterns: 1) an
impaired relaxation” pattern (E/A ratio 1); 2) a “restric-
ive” pattern when the E/A ratio was 2, or between 1 and
with an E-wave deceleration time (DT) 130 ms, or DT
130 ms alone in case of atrial fibrillation; and 3) a
pseudonormal” or “normalized” pattern when the E/A ratio
as between 1 and 2 and the E-wave DT 130 ms. The
itral Doppler pattern was unavailable in eight patients
ecause of poor echogenicity, tachycardia, permanent pac-
ng, or mitral prosthesis. Systolic pulmonary arterial pres-
ure was calculated from the velocity of tricuspid regurgita-
ion, when present. The LVEF was estimated by Simpson’s
ethod.
tatistical analysis. Categorical data are presented as num-
ers (percent), and continuous data as means  SD.
og-transformed values for BNP were used in these anal-
ses to reduce the effects of skewness in the distribution of
NP values. Student t test and Fisher exact test were used
hen indicated. Group comparisons of BNP values were
ade by using analysis of variance with the Newman-Keuls
ost hoc test. We used Cox proportional hazards regression
odels to examine the relation of clinical variables, BNP
evels, and echocardiographic findings with the incidence of
rimary end point (death or re-admission for CHF) or alone
e-admission for CHF within the first month and at six
onths after discharge. B-type natriuretic peptide levels
ere evaluated both as a continuous variable (with increases
n risk calculated per increment of 100 ng/l) and as a categorical
ariable (based on distribution quartiles). Percentage change in
NP level ([BNP “admission”  “predischarge ” BNP]
 100/BNP “admission”) was also evaluated as a contin-
ous variable (with decreases in risk calculated per decrease
f 10%) and as a categorical variable. Analyses were adjusted
or the following baseline covariables: age, diabetes mellitus,
nd LVEF (well-known predictors of mortality), inotropic
rug use, and Doppler mitral pattern (associated with
utcome in this study). Receiver operating characteristics
ROC) curves were constructed to illustrate various cut-off
alues of BNP. P values 0.05 were considered significant.
nalyses were performed using STATA 8.0 software for
indows (Stata Corporation, College Station, Texas).
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February 18, 2004:635–41 BNP Assay and Heart Failure OutcomeESULTS
erivation study: outcome and predictors of outcome.
ll the 114 patients were admitted because of severely
ecompensated CHF (New York Heart Association class
V); 83 patients had pulmonary edema, 12 had cardiogenic
hock, and 24 required inotropic agents and/or mechanical
entilation. Main characteristics are summarized in Table 1.
ine patients died of refractory CHF during the initial
ospital stay. The 105 surviving patients were discharged
ome in New York Heart Association class II to III and had
o more symptoms at rest, no rales, no gallop, no severe
ypotension (defined as systolic blood pressure 80 mm
g). Mean BNP levels were 1,015 604 ng/l at admission,
81  615 ng/l at 24 h, 638  560 ng/l at 48 h, and 457 
02 ng/l predischarge (Fig. 1). B-type natriuretic peptide
evels did not decrease, or fell by 50 ng/l, in 11 patients
etween admission and discharge. Predischarge Doppler-
chocardiographic examination showed a systolic dysfunc-
ion (LVEF 45%) in 70% of patients, “impaired relax-
tion,” “pseudonormal,” and “restrictive” mitral patterns in
8%, 33%, and 29% of patients, respectively.
During the six months of follow-up, 12 patients died, and
able 1. Main Characteristics of the Patients in the Two
roups and Adverse Events After Discharge
Derivation
Study
(n  114)
Validation
Study
(n  109) p Value
Age (yrs) 69.4  14.4 70.9  13.3 0.45
Age 75 yrs (n, %) 50 (44%) 32 (43%) 0.85
Gender (male/female) 79/35 56/53 0.003
Ischemic etiology (n, %) 44 (39%) 45 (42%) 0.50
LVEF 37.5  14.9 31.8  14.5 0.17
Use of inotropes (n, %) 25 (22%) 34 (32%) 0.07
In-hospital death (n, %) 9 (8%) 12 (11%) 0.64
BNP at admission (ng/ml) 1,015  604 941  526 0.68
BNP at discharge (ng/ml) 457  451 441  501 0.80
utcome after discharge n  105 n  97
Cardiac death (n, %) 12 (11%) 9 (9%) 0.64
First re-admission (n, %) 39 (37%) 26 (27%) 0.21
NP  B-type natriuretic peptide; LVEF  left ventricular ejection fraction.
igure 1. Box plots showing median predischarge levels of B-type natri-
retic peptide (BNP) from admission to discharge (derivation study). Meanevels are indicated in the box.9 were re-admitted for unscheduled CHF; 29% of these
vents occurred during the first month, and the mean time
rom discharge to the first event was 72  48 days. Table 2
hows the results of univariate Cox analysis for each clinical
ariable, creatininemia, echocardiographic findings, and se-
ial BNP measurements as predictors of death or re-
dmission. Among clinical variables, only the use of inotro-
ic drugs was associated with adverse outcome. Among
chocardiographic variables, LVEF was poorly predictive
hile the predischarge Doppler mitral pattern was strongly
ssociated with death or re-admission. Serial BNP measure-
ents were also predictive of outcome as well the percent-
ge change between admission and subsequent assays. The
redischarge BNP level was the value most strongly associ-
ted with death or re-admission and the most discriminative
area under ROC curve  0.80 [0.71 to 0.89] vs. 0.69 and
.68 for previous BNP assays and 0.76 for percentage
hange).
In multivariate analysis including clinical variable, echo-
ardiographic findings, the predischarge BNP level, and the
ercentage change in BNP levels, only the predischarge
NP level remained significant (hazard ratio [HR]  1.14
1.02 to 1.28], p  0.027). Using the predischarge BNP
evel (as a continuous variable and after adjustment for
ovariables), similar results were obtained for: 1) death or
e-admission at one month (HR  1.17 [1.06 to 1.28], p 
.002); and 2) re-admission at six months (HR 1.25 [1.16
o 1.34], p  0.001). At last, a BNP level of 350 ng/l was
ound to have the best compromise between sensitivity and
pecificity for predicting death or re-admission at six
onths (Fig. 2).
alidation study. Main characteristics of the validation
ample are summarized in Table 1. Patients enrolled in this
ample differed from those enrolled in the derivation sample
nly for gender and inotropic drugs use. Among the 109
ncluded patients, 12 died during the hospitalization, nine
ied during the six months follow-up, and 26 were rehos-
italized for decompensated HF. Mean BNP levels were
41  526 ng/l at admission, 693  440 ng/l at day 1, and
41  501 mg/l at discharge. Among serial BNP measure-
ents, predischarge BNP level remains a strong predictor of
eath or re-admission in the validation sample (area under
OC curve  0.83 [0.69 to 0.97]). Event-free patients had
ean predischarge BNP levels of 247  201 ng/l compared
ith 908  809 ng/l for patients with adverse events (p 
.001). Applying the predefined BNP cut-off level of 350
g/l, death or re-admission at six months was predicted
ith a sensitivity of 80% and a specificity of 88%.
Figure 3 shows Kaplan-Meier curves according to pre-
efined BNP cut-off (350 ng/l); predischarge BNP levels
350 ng/l strongly related to death or re-admission (HR 
2.6 [5.7 to 28.1], p  0.0001), and the rate of events
eached 23.5% at one month and 79.4% at six months,
ompared with 0% and 12.7% for predischarge BNP levels
350 ng/l.
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BNP Assay and Heart Failure Outcome February 18, 2004:635–41raded relation between predischarge BNP levels and
utcome. We constructed Kaplan-Meier curves with the
redischarge BNP values from the whole population (i.e.,
erivation and validation samples) (Fig. 4). The risk of
eath or re-admission increased in stepwise fashion across
ncreasing predischarge BNP ranges: 350 ng/l, 350 to 700
Table 2. Univariate Cox Analysis Showing the
Risk of Death or Re-Admission During the Si
Variables
Age (yrs), per five-year increase
Gender (male)
Ischemic
Diabetes
Atrial fibrillation
Creatininemia
Inotropic use
LVEF
Doppler mitral pattern
“Abnormal relaxation” pattern
“Pseudo-normal” pattern
“Restrictive” pattern
Serial BNP
BNP admission, per 100 ng/l increase
BNP day 2, per 100 ng/l increase
BNP predischarge, per 100 ng/l increase
Percentage decrease BNP, per 10% decrease
BNP predischarge (per quartile of distribution)
First quartile (0–130)
Second quartile (130–370)
Third quartile (370–660)
Fourth quartile (660–1,725)
Percentage decrease BNP (per quartile of distributio
First quartile (38%)
Second quartile (38%–63%)
Third quartile (63%–79%)
Fourth quartile (79%)
BNP  B-type natriuretic peptide; CI  confidence interva
Percentage decrease BNP  (BNP admission  predischarg
igure 2. Receiver operating characteristic (ROC) curve for predischarge
-type natriuretic peptide (BNP) cut-off values and association with deathsr re-admission at six months (derivation study).g/l, 700 ng/l (p  0.001); this relation was unchanged
fter adjustment for age, LVEF, diabetes mellitus, and the
se of inotropic drugs. Patients with BNP 350 ng/l had
he best outcome (16.2% of events at 6 months) compared
ith patients with BNP between 350 and 700 ng/l (60.0%,
R 5.1 [2.8 to 9.1]) and patients with BNP 700 ng/l
92.7%, HR 15.2 [8.5 to 27]).
ISCUSSION
his prospective study documents and validates that high
redischarge blood BNP levels are a strong predictor of
hort-term death or re-admission after acute hospital care
or decompensated CHF. This relationship between predis-
harge BNP and outcome is graded. The prognostic infor-
ation of predischarge BNP assay is greater than are
ommon clinical variables, BNP change during the in-
ospital stay, and Doppler echocardiographic findings. The
wo samples consisted of unselected patients with a wide
ange of ages and LVEF values (preserved LVEF, i.e.,
0.45, in 30% of patients), similar to that encountered in
outine practice, and successively included in two different
ospitals. The very high rate of post-discharge adverse
vents was in keeping with the results of other studies of
nselected community-dwelling patients (1–5,20). Stratifi-
ation for subsequent treatment (titration of medications
ciation Between Various Variables and the
nths of Follow-up in the Derivation Study
HR 95% CI p Value
1.03 0.93–1.13 0.6
0.87 0.49–1.56 0.6
1.14 0.65–2.0 0.6
1.16 0.58–2.32 0.7
0.61 0.30–1.26 0.2
1.02 0.98–1.06 0.3
2.34 1.26–4.34 0.007
0.95 0.78–1.16 0.6
1
3.27 1.43–7.49 0.005
6.30 2.78–14.25 0.0001
1.06 1.03–1.10 0.0001
1.07 1.03–1.11 0.0001
1.22 1.15–1.30 0.0001
0.84 0.77–0.90 0.0001
1
2.94 0.92–9.37 0.07
4.42 1.45–13.45 0.009
13.77 4.71–40.23 0.0001
1
0.94 0.49–1.81 0.85
0.40 0.19–0.87 0.02
0.18 0.07–0.48 0.001
 hazard ratio; LVEF  left ventricular ejection fraction;
P)/BNP admission.Asso
x Mo
n)
l; HRuch as diuretics, visits, and so forth) is, therefore, impor-
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February 18, 2004:635–41 BNP Assay and Heart Failure Outcomeant. In our study, clinical variables were poorly predictive of
ost-discharge outcome, with the exception of inotropic use
uring acute care. All patients were judged to be stable at
ischarge, even though, respectively, 15% of them were
e-admitted or died during the first month and more than
0% during the first six months after discharge. In practice
t is difficult to evaluate, using clinical criteria, the stability
f such weakened and sometimes bedridden patients after
everal days of aggressive treatment. Indeed, clinical judg-
ent correlates poorly with tests of cardiac function (21,22).
oreover, a number of tests with known prognostic value,
uch as invasive hemodynamic measurements and stress
esting of aerobic capacity, are unusable in many of these
atients. Nevertheless, Doppler-echocardiographic exami-
ation results in criteria of prognostic significance, which
an be easily obtained, even in this setting, and are widely
igure 3. Kaplan-Meier curves showing the cumulative incidence of deat
ut-off value of 350 ng/l in the validation study; p  0.0001.
igure 4. Kaplan-Meier curves showing the cumulative incidence of deat
anges (350, 350 to 700, 700 ng/l) in the whole population; p  0.00
ach BNP range.dmitted. While LVEF had poor prognostic value in the
wo population samples of our study, the Doppler mitral
nflow pattern was predictive, and “restrictive” and “pseudo-
ormal” patterns before discharge were associated with
dverse outcome. The “restrictive” pattern is a widely used
rognostic index in various settings (9,10,23–25), whereas a
pseudonormal” pattern has rarely been linked to poor
utcome of CHF (11).
B-type natriuretic peptide measurement, a simple biolog-
cal test, is appropriate to this acute setting. In univariate
ox analysis, all BNP measurements from admission to
ischarge, as well as the percentage change, were signifi-
antly associated with the risk of death or re-admission after
ischarge, but the predischarge assay was the most valuable.
fter adjustment for age, diabetes mellitus, and LVEF
usual predictors of mortality), and for inotropic drug
e-admission according to predischarge B-type natriuretic peptide (BNP)
e-admission according to predischarge B-type natriuretic peptide (BNP)
the trend among BNP ranges. On the right, hazard ratios are shown forh or rh or r
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BNP Assay and Heart Failure Outcome February 18, 2004:635–41equirements (the only predictive clinical variable found
ere), predischarge BNP levels remained strongly predictive
f death or re-admission after both one month and six
onths of follow-up. Recently, changes in the BNP level
uring early aggressive treatment were closely associated
ith falling pulmonary wedge pressure in patients treated
or decompensated CHF (26). In addition, Cheng et al. (27)
eported that changes in serial BNP levels during hospital
are were predictive of outcome, but BNP was not com-
ared with other parameters, and end points combined
n-hospital deaths and post-discharge events. In this study,
ery high mean BNP levels at discharge (more than 1,500
g/l) and no decrease during treatment in patients who died
r were re-admitted suggest that the patients were very
everely sick. In our study, the percentage change in BNP
evels during acute care had less prognostic value than the
redischarge measurement alone. B-type natriuretic peptide
evels are mainly determined by LV wall stress. The predis-
harge BNP level may, thus, reflect the decrease in LV
lling pressure and the degree of hemodynamic stability,
hich is achieved after acute treatment, as well as the
everity of underlying diastolic dysfunction, and is a major
redictor of early outcome. Interestingly, BNP level and
oppler mitral pattern have similar significance from a
echanistic point of view, as LV filling pressure and LV
all stress are major determinants of both BNP levels (28)
nd Doppler mitral pattern (29,30). The E-wave DT
orrelated negatively with BNP levels in our study (data not
hown), and the predischarge “restrictive” Doppler pattern
suggesting lasting high LV filling pressure or severe dia-
tolic dysfunction) was associated with the highest BNP
evels at discharge. Finally, Doppler analysis of mitral inflow
dded no significant prognostic information to BNP mea-
urement when the two parameters were included in mul-
ivariate Cox models. A predischarge BNP level at 350
g/ml appeared the more relevant cut-off to predict adverse
utcome in our two samples of patients. In fact, the risk of
eath or re-admission increased in stepwise fashion across
ncreasing predischarge BNP ranges; a dramatic increase in
he risk of events was observed from 350 ng/l, and BNP
700 ng/l was associated with a major risk (31% of death or
e-admission for CHF at one month and 93% at six
onths). These levels, like those reported by Cheng et al.
27), are higher than the values generally reported in
utpatients (17,18). Among 85 selected outpatients with
ymptomatic CHF and systolic dysfunction, Tsutamoto et
l. (17) found that the median BNP level (73 ng/l) distin-
uished subsequent survivors from nonsurvivors. Berger et
l. (19) recently proposed a cut-off of 130 ng/l. These
ifferences in BNP cut-offs reflect differences in the dura-
ion of follow-up and in the study populations (e.g.,
ospitalized patients vs. outpatients).
linical implications. The high rates of early re-admission
bserved in this study suggest that many CHF patients are
ischarged without sufficient circulatory stabilization, de-
pite the clinician’s impression to the contrary. The singleredischarge BNP assay is strongly predictive of early
utcome, regardless of the initial BNP level (and in-hospital
hanges) and echocardiographic findings; thus, it appears to
e a simple and reliable test to identify the highest risk
atients. Further studies are required to determine if serial
NP assay can improve patient management, for example
y determining the optimal timing of discharge and subse-
uent care requirements, as recently suggested (31).
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